Clinical intervention trials reveal resveratrol’s capacity to recalibrate this redox-inflammatory axis: a 40-day regimen in PCOS patients (n=20) demonstrated significant reductions in IL-6, IL-1β, TNF-α, IL-18, NF-κB, and CRP (92). This evidence concerns the gene IL18 and polycystic ovary syndrome.